Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma

Na Sun1†, Marija Trajkovic-Arsic2,3†, Fengxia Li1†, Yin Wu1, Corinna Münch2,3, Thomas Kunzke1, Annette Feuchtinger1, Katja Steiger4,5, Anna Melissa Schlitter4,5, Wilko Weichert4,5,6, Irene Esposito7, Jens T. Siveke2,3* and Axel Walch1*

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies to date. The impressively developed stroma that surrounds and modulates the behavior of cancer cells is one of the main factors regulating the PDAC growth, metastasis and therapy resistance. Here, we postulate that stromal and cancer cell compartments differentiate in protein/lipid glycosylation patterns and analyze differences in glycan fragments in those compartments with clinicopathologic correlates.

Results: We analyzed native glycan fragments in 109 human FFPE PDAC samples using high mass resolution matrix-assisted laser desorption/ionization Fourier-transform ion cyclotron resonance mass spectrometric imaging (MALDI-FT-ICR-MSI). Our method allows detection of native glycan fragments without previous digestion with PNGase or any other biochemical reaction. With this method, 8 and 18 native glycans were identified as uniquely expressed in only stromal or only cancer cell compartment, respectively. Kaplan–Meier survival model identified glycan fragments that are expressed in cancer cell or stromal compartment and significantly associated with patient outcome. Among cancer cell region-specific glycans, 10 predicted better and 6 worse patient survival. In the stroma, 1 glycan predicted good and 4 poor patient survival. Using factor analysis as a dimension reduction method, we were able to group the identified glycans in 2 factors. Multivariate analysis revealed that these factors can be used as independent survival prognostic elements with regard to the established Union for International Cancer Control (UICC) classification both in tumor and stroma regions.
Background
Pancreatic ductal adenocarcinoma (PDAC) remains one of the least understood malignancies to date, resulting in lack of targeted and immune-based approaches. Though molecular characterization and subtyping into two major subtypes [1–3], classical and basal-like/quasi-mesenchymal, have brought transcriptome-based patient stratification into focus, the underlying biology of PDAC with regard to progression and therapy resistance remains largely elusive [4]. Desmoplastic stroma that surrounds and modulates the phenotype of cancer and immune cells within the tumor microenvironment is a hallmark of PDAC and likely a direct modulator of disease progression [5]. The stroma, consisting mainly of extracellular matrix (ECM), blood vessels and ECM-producing fibroblasts, creates a setting that communicates with cancer and immune cells and modulates tumor growth, metastasis and drug resistance. Identifying molecules differentially expressed in the stroma and cancer cell compartment may allow better understanding of cancer–stroma communication and development of technologies for compartment-specific targeting and stromal modulation.

Glycans are sugar moieties, oligosaccharides or polysaccharides, that when attached to proteins and lipids create glycoconjugates. Glycans present very diverse structures, have shorter or longer, branched or linear sugar chains and are additional modified by sulfation, phosphorylation, etc. Depending on how the sugars are attached to the protein/lipid molecule, glycoconjugates are clustered in four general groups: (i) N-linked glycoproteins where sugar motifs are attached to asparagine, (ii) O-linked glycoproteins where sugars are attached to serine/threonine, (iii) heavily glycosylated proteoglycans with one or more glycosaminoglycans (GAG) attached and (iv) glycolipids. It is estimated that 50–70% of all human proteins are post-translationally glycosylated and correct glycosylation is essential for proper cellular localization and function of the protein or lipid. Glycosylation fundamentally influences protein trafficking, stability and forming, and many proteins and lipids involved in essential physiological processes such as cell–cell communication, cell–ECM communication, protein folding and signal transduction are glycosylated. It has been shown that in tumors, including PDAC, altered glycosylation is involved in tumor-related processes of cell adhesion, proliferation, invasion, metastasis and angiogenesis [6, 7]. Typical cancer-associated glycosylation changes include sialylation, fucosylation, O-glycan truncation and N- and O-linked glycan branching [7], all present in PDAC as well. For example, interaction of tumor-associated sialyl Lewis antigen (SLe\(^x\)) with endothelial adhesion molecules selectins allows extravasation of cancer cells and metastatic spread [8]. In PDAC, abundance of SLe\(^x\) predicts development of liver metastasis [9]. Truncated O-glycans have been detected on EGFR in pancreatic cancer [10], increased N-glycosylation and branching on integrins and ECM proteins [11], and increased fucosylation is detected in serum of PDAC patients [12]. Furthermore, the main glycan synthesis pathway, the hexosamine biosynthesis and consecutive O-glycosylation are strongly upregulated in highly resistant hypoxic PDAC cells [13].

Tumor stroma supports the cancer progression in multiple ways. Growth factors, adhesion molecules, nutrients are all produced by the stromal cells and locally provided to the proliferating cancer cell. There is whole plethora of interactions observed between glycosylated stromal proteins and cancer cells, all serving the function of cancer progression, invasion and metastasis (reviewed in [14]). Stromal ECM provides a settling niche for cancer and immune cells, and next to collagen fibers, glycosylated proteoglycans are the main component of tumor ECM. Proteoglycans are comprised of one or several glycosaminoglycans (GAG) with repeats of chondroitin sulfate (CS), heparan sulfate (HS) and dermatan sulfate (DS) covalently attached to protein core. Proteoglycans are mainly produced by the cancer-associated fibroblasts (CAFs) in the stroma and play a role in intercellular and ECM interactions via activation of receptor tyrosine kinases (EGFR, FGFR, IGF1R, INSR) on the cancer cells [14] regulating the proliferation and survival cascaded. Furthermore, stromal proteoglycans communicate with cancer cell membrane integrins and regulate cells motility and invading potential [14].

Due to their cancer-specific expression and function, proteins with altered glycosylation are highly attractive as potential biomarkers, targets for therapeutic agents and targeted drug delivery [15]. The diversity of glycosylated proteins and lipids and their functions in cancer opens these perspectives. However, which glycans are typically enriched in cancer cells and which specifically in the stromal compartment, respectively, has not been

**Conclusion:** Our method allows in situ detection of naturally occurring glycans in FFPE samples of human PDAC tissue and highlights the differences among glycans found in stromal and cancer cell compartment offering a basis for further exploration on the role of specific glycans in cancer–stroma communication.

**Keywords:** MALDI-FT-ICR-MSI, Glycans, PDAC
addressed yet. PDAC is one of the most stroma-rich solid tumors where desmoplastic reaction consumes 50–80% of the tumor tissue and can even be stratified to “normal” and “activated” stroma with later having worse prognosis [16]. Defining glycans that are differentially expressed in cancer cell or stromal compartment may improve our understanding of the stroma–cancer cell interaction and indeed allow better, compartment targeted therapeutic approaches.

In this work, we report on high mass resolution matrix-assisted laser desorption/ionization Fourier-transform ion cyclotron resonance mass spectrometric imaging (MALDI-FT-ICR-MSI)-based detection of prominent differences in native glycan fragments distribution among cancer and stromal compartments in human PDAC FFPE tissue samples. Previously performed glycan mass spectrometry studies on PDAC tissue used digestion methods for release of N-glycan structures from the protein core [17]. Enzymatic degradation of tissue increases measurability but hinders the differentiation among naturally occurring glycans and those previously bound [18]. Our MALDI-FT-ICR-MSI is performed on FFPE PDAC samples without previous tissues digestion with PNGase F or other biochemical process allowing detection of naturally occurring native glycan fragments, products of tissue-specific proteoglycan/GAG degradation. We classify differentially expressed glycans in cancer cells and the tumor stroma, which may have prognostic and functional relevance in PDAC progression. This glycan map may thus serve as a reference for further glycan-based diagnostic and targeting approaches.

Methods

Tissue microarray (TMA) preparation

Tissue microarrays (TMAs) were constructed using formalin-fixed paraffin embedded resected Pancreatic Ductal Adenocarcinoma (PDAC) specimens from 109 patients. The study was approved by the ethics committee of the Technical University of Munich, Germany (documents no. 1926/2007 and 126/2016S). Written informed consent was obtained from every patient. Representative tumor areas were identified by an experienced pathologist, and three cores with 1 mm diameter from each sample were transferred into the microarray.

MALDI-FT-ICR MSI analysis and data processing

The FFPE samples were cut into 3 μm sections on a paraffin microtome (HM 355S, Microm, Thermo scientific), mounted onto the ITO-coated glass slides. The FFPE sections were incubated at 60 °C for 1 h, deparaffinized in xylene (2 × 8 min) and dried on a hot plate at 37 °C. The matrix solution consisted of 10 mg/ml 9-aminoacridine hydrochloride monohydrate (9-AA) (Sigma-Aldrich, Germany) in water/methanol 30:70 (v/v). SunCollect™ automatic sprayer (Sunchrom, Friedrichsdorf, Germany) was used for matrix application. The flow rates were 10, 20, 30 and 40 μl/min, respectively, for the first four layers. The other four layers were performed at 40 μl/min. The MALDI-MSI measurement was performed on a Bruker Solarix 7T Fourier-transform ion cyclotron resonance mass spectrometer (FT-ICR-MS) (Bruker Daltonik, Bremen, Germany) in negative ion mode using 50 laser shots per spot at a frequency of 500 Hz. The MALDI-MSI data were acquired over a mass range of m/z 50–1000 with 50 μm lateral resolution. The acquired data from the tissue samples were underwent spectra processing in FlexImaging v. 4.0 (Bruker Daltonics, Germany). MALDI-MSI data were normalized to the root mean square of all data points. Cancer cell and stroma regions were annotated as regions of interest (ROIs). The average spectral data of ROIs were then exported to peak list as.csv files from FlexImaging software.

MATLAB® R2014b (v.7.10.0, Mathworks, Inc., Natick, MA) was used as MALDI spectral preprocessing tool for the subsequent data bioinformatics analysis. The exported.csv files including all mass spectra from cancer cell and stroma regions are loaded into MATLAB® R2014b and underwent resampling, smoothing and baseline subtraction to lower the data dimensionality and to remove the noise-level peaks and artefacts. Peak picking was performed using an adapted version of the LIMPIC algorithm [19] with m/z 0.0005 minimal peak width. The signal-to-noise and intensity threshold were set to 2 and 0.01%, respectively. Isotopes were automatically identified and excluded.

Glycan annotation

The peak list was submitted to glycan annotation using the PeakFinder tool (http://www.eurocarbdb.org/ms-tools/), which was included in GlycoWorkbench ver 2.1 build 146 (http://www.eurocarbdb.org/) [20]. The search parameters were a 4 ppm mass tolerance and a negative charge. Additionally, human Metabolome Database (http://www.hmdb.ca/) was used as supplementary database for annotation of the glycan peaks.

Kaplan–Meier analysis and statistical analysis

In order to determine the prognostic power for each identified glycan, the individual patient glycan fragment abundances were used to split the cohort into good and poor survivor groups by the application of intensity cutoffs, which were optimized to the clinical endpoint. Cutoff-optimized survival analyses were performed as previously described [18, 21] using a Kaplan–Meier Fitter and log-rank test. Cutoff optimized in this context means that the threshold for low and high abundance
of a compound was chosen such that the \( p \) value in the resulting Kaplan–Meier curve is minimal. Cutoff points and patients survival table are given in Additional file 2: Table S1. Overall survival rates were calculated using the Kaplan–Meier method and included 95% confidence interval estimates. Survival curves were tested with the log-rank \( \chi^2 \) value and Cox proportional hazards regression analysis. Univariate and multivariate analysis was performed using Cox proportional hazards regression models. In a Cox regression, the coefficients of predicate variables relate to hazard and the hazard ratio (HR) of a predicate variable is given by the exponent of its coefficient. All statistical analyses were performed within the R statistical environment (R Foundation for Statistical Computing, Vienna, Austria), in which \( p \) values \( \leq 0.05 \) were considered statistically significant.

Through factor analysis, a smaller set of analyzed variables could be group into “factors” with common characteristics [22]. Factor analysis provides a way of extracting underlying “factors” or “factor constructs” which accounts for the inter-correlations among the variables [23, 24]. It serves as a good procedure to identify the factors that summarize the “good” or “poor” prognostic glycan fragments identified in MALDI-MSI analysis. Previous studies have attempted to apply similar analysis for identifying latent factors and to use these factors to stratify patients for survival analysis [25]. In this study, the analyses were done using factor analysis function (“fa”) from R “Psych” package. Default factoring method (“minres”) and rotating method (“oblimin”) were applied. To explore the optimal factor numbers to extract, fa.parallel function was applied for the “screen plot” which helps determining the factor numbers to extract. Factor analysis generates factor scores for each unraveled factor. As a summarization of the variation of a set of related original variables, factor score represents the variation of extracted “factor” variable among samples and can be used in subsequent analyses [26]. In this study, factor scores are applied in Kaplan–Meier analysis and multivariate survival analysis.

**Results**

**Patient characteristics and data acquisition**

The MALDI-FT-ICR MSI analysis included 109 PDAC patients. Detailed clinical characteristics of PDAC patients are shown in Table 1. Within the mass range of \( m/z \) 50 to 1000, approximately 2000 individual MS peaks per pixel could be resolved. With 50 \( \mu \)m lateral resolution, the MSI spectra data of more than one million pixels were extracted and subjected to metabolic database and bioinformatics analysis.

| Characteristic | Number (% of patients or median (range)-tumor regions) |
|---------------|----------------------------------------------------------|
| Number of patients | 109 |
| Male Sex, number (% | 60 (55) |
| Age at initial diagnosis (years) | 69 (32–87) |
| Survival time (months) | 17 (3–69) |
| Status complete | 84 (77) |
| UICC tumor stage at initial diagnosis, number (%) | |
| I | 5 (5) |
| II | 83 (76) |
| III | 13 (12) |
| IV | 8 (7) |

**Mass spectrometry imaging reveals differences in glycan distribution in tumor and stroma regions**

PDAC tissue cores were investigated for regions rich in cancer cells (hereafter always named as “cancer cell region”) and stroma region and were manually annotated. For glycan annotation, GlycoWorkbench and HMDB database were used. As a result, 41 native glycan fragments were detected in cancer cell regions, and 31 glycan fragments were identified in the stroma region. Both unique and common glycans could be detected in cancer cell and stromal regions. The Venn diagrams show 23 glycans commonly identified in cancer cell and stroma regions (Fig. 1B). List of glycan fragments and their localization are summarized in Table 2. Additionally, differences among glycan fragments found in cancer cell and stroma region could be observed as indicated by orthogonal partial least squares discriminant analysis (ortho-PLSDA) (Fig. 1A). As an example, in Fig. 1C two differentially distributed glycan fragments in one tissue core are co-visualized, showing a distinct enrichment of Hex-HexNAcS in the cancer cell region and N-Acetylgalactosamine sulfate in the stroma region.

In addition, of all identified masses, intensities for 3 glycan fragments (HexHexHexNAcS, HexHexHexNAcHexNAcS and HexHexNAcS) were significantly correlating with tumor grade (G1–G3 grades), with usually highest intensities measured in grade 1 PDACs (Additional file 1: Fig. S1).

**Impact of native glycan fragments on prognosis**

To determine whether glycans expressed in cancer cell or stroma region are associated with clinical outcome, we performed Kaplan–Meier analyses with overall survival as endpoint.
In the cancer cell region, Kaplan–Meier survival model identified 16 glycan fragments to be significantly associated with patient outcome (Fig. 2A, Table 3). Ten glycan fragments presented hazard ratio (HR) lower than 1 (HR < 1; 95% confidence interval (CI)), indicating favored prognosis for patients with high abundance of these glycans in the cancer cell region. The remaining 6 glycan fragments showed a HR > 1 (95% CI), indicating poor prognosis for patients with high abundance of these fragments.

In the stroma region, 5 glycan fragments with potentially prognostic value were identified (Fig. 2B, Table 3). High abundance of HexS was associated with good patient outcome (HR = 0.50; 95% CI). Increased intensity of the remaining four molecules corresponded to an unfavorable patient prognosis (HR > 1; 95% CI).

In addition, we also performed a multivariate analysis of the identified “prognosis significant” glycan fragments with UICC staging (Additional file 3: Table S2). Four glycan masses, dHexPenHexAc and dHexHexHexAMe in cancer cell region, HexS and HexANAcS in stroma region, served as an independent prognostic factor with regard to the Union for International Cancer Control (UICC) stage.

**Factor analysis**

To generate independent glycan prognostic factor, factor analysis as a dimension reduction method was applied. This procedure analyzes the structure of a dataset by identifying the interrelationships among a set of various observed variables. In the cancer cell region, a clear separation of “good” prognosis fragments from “poor” prognosis fragments is achieved in the 2-factor result. Eight of 10 glycan fragments positively associated with favored patient outcome are grouped in Factor 1, while 5 of 6 fragments positively associated with poor patient outcome are grouped in Factor 2 (Fig. 3A).

In the stroma region, the glycan fragment HexS was associated with favorable patient outcome. The other 4
Table 2 List of annotated glycan fragments

| Annotation                                      | MW      | Cancer cell and/or stroma region          |
|-------------------------------------------------|---------|------------------------------------------|
| HexA                                            | 193.0350| Cancer cell/stroma                       |
| N-Acetylhexosamine                              | 202.0720| Cancer cell/stroma                       |
| HexS                                            | 259.0135| Cancer cell/stroma                       |
| HexP                                            | 259.0225| Cancer cell/stroma                       |
| N-Acetylhexosamine sulfate                      | 282.0290| Cancer cell/stroma                       |
| HexHex                                          | 341.1090| Cancer cell/stroma                       |
| NeuGcAc                                         | 366.1030| Cancer cell/stroma                       |
| Chondroitin or hyaluronan                       | 378.1050| Cancer cell/stroma                       |
| dHexHexANAcMe                                   | 394.1360| Cancer cell/stroma                       |
| HexAHexNAc                                      | 396.1677| Cancer cell/stroma                       |
| N-Acetylhexosamine disulfate                    | 401.9785| Cancer cell/stroma                       |
| HexNS3                                          | 417.9440| Cancer cell/stroma                       |
| HexNAcHexNAc                                    | 423.1620| Cancer cell/stroma                       |
| HexHexNAcNAc                                    | 424.1463| Cancer cell/stroma                       |
| HexANAcHexNAc                                   | 437.1397| Cancer cell/stroma                       |
| Chondroitin sulfate                             | 458.0605| Cancer cell/stroma                       |
| HexHexNAcS                                      | 462.0937| Cancer cell/stroma                       |
| HexAHexNAcS                                     | 476.0725| Cancer cell/stroma                       |
| dHexHexPenHexAc                                 | 499.1677| Cancer cell/stroma                       |
| dHexHexHexANMe or Hex2PenAc                     | 515.1625| Cancer cell/stroma                       |
| PenHexAHexNAc                                   | 528.1555| Cancer cell/stroma                       |
| HexNAcHexHexNAc or NeuAcAc                      | 599.1555| Cancer cell/stroma                       |
| PenPenHexAHexMePenHexANMe                      | 793.2255| Cancer cell/stroma                       |
| dHexHexN                                        | 324.1300| Cancer cell/stroma                       |
| HexNAcHexNAcAcAc                                | 346.1140| Cancer cell                              |
| NeuAcAc                                         | 350.1090| Cancer cell                              |
| dHexHexS                                        | 405.0710| Cancer cell                              |
| HexNAcHexNAcS                                   | 503.1175| Cancer cell                              |
| PenPenHexAc                                      | 527.1625| Cancer cell                              |
| HexAHexAHexMeMe or HexHexHexAc                  | 559.1510| Cancer cell                              |
| HexHexHexS                                      | 583.1190| Cancer cell                              |
| KdoHexAHexA                                      | 589.1270| Cancer cell                              |
| HexHexHexNAcS                                   | 624.1455| Cancer cell                              |
| HexHexNAcHexNAcS                                 | 665.1725| Cancer cell                              |
| HexHexHexHexAc or PenPenPenPenHex               | 707.2260| Cancer cell                              |
| HexNAcPHexNeuAc                                 | 753.1975| Cancer cell                              |
| dHexHexHexHexSial HexNAc                        | 770.2043| Cancer cell                              |
| HexHexHexANAcHexlHexNAcS                       | 827.2520| Cancer cell                              |
| HexHexPenHexAHexNAc                             | 852.2610| Cancer cell                              |
| HexHexPenHexHexAc                               | 869.2800| Cancer cell                              |
| dHexHexPenHexPenHexHex                          | 897.3110| Cancer cell                              |
| PenHexNAc                                       | 352.1250| Stroma                                   |
| HexMeHexNAc                                     | 396.1500| Stroma                                   |
| dHexHexHexNAcS                                  | 446.0990| Stroma                                   |
| HexHexHexMe                                     | 517.1790| Stroma                                   |
| HexNAcHexHexHexPen                              | 644.2397| Stroma                                   |
| dHexHexHexHexHexANMe or dHexHexHexHexPenAc      | 645.2233| Stroma                                   |
| PenPenHexHexHexSMe                              | 683.1730| Stroma                                   |
| HexNAcHexNeuAcMeMe                              | 701.2640| Stroma                                   |

Table 2 (continued)

- Hex hexose, dHex deoxy hexose, Pen pentose, HexA hexuronic acid, HexN hexosamine, HexNAc N-acetylhexosamine, NeuAc N-acetyl neuraminic acid, NeuGc N-glycolyl neuraminic acid, S sulfate, P phosphate, Ac acetate; NAc N-acetate, Me methyl

glycan fragments were grouped as “poor” prognosis factor (Fig. 3B).

Multivariate analysis reveals distinct glycan patterns as independent prognostic factors

In this study, generated factor scores were applied in a multivariate analysis. In this way, the adverse influence of multiple inter-correlations among the glycans on multivariate survival modeling is mitigated. Multivariate survival model for the tumor regions integrated UICC tumor stage with Factor 1 and Factor 2. The result revealed that in cancer cell region, both Factor 1 (p = 0.024, HR = 0.20) and Factor 2 (p = 0.011, HR = 2.06) serve as independent prognostic factor with regard to the established UICC classification (p = 0.007, HR = 1.55) (Table 4). For the stroma region, multivariate model was applied to UICC tumor stage, the good prognoses Factor 1 and poor prognoses Factor 2. The result demonstrated the independent prognostic power of Factor 1 (p = 0.017, HR = 0.56) and Factor 2 (p = 0.031, HR = 2.10) with regard to UICC staging (p = 0.002, HR = 1.65) in the stroma region (Table 4).

Discussion

Considering the late diagnosis, high intrinsic and acquired resistance to chemotherapies and the resulting high mortality in PDAC, identification of early disease biomarkers and novel targets are a priority task to improve clinical outcome. Recent studies suggest that the heavily developed tumor stroma in PDAC is actively participating in PDAC biology and influences the clinical outcome [16]. Particularly cancer-associated fibroblasts (CAFs) not only produce the ECM but actively support inflammatory and migratory actions of cancer and immune cells [27]. Knowledge about molecules specifically expressed on stromal and cancer cell compartment may allow development of strategies for disruption of cancer cell–stroma synergy and provide clinical improvement. Protein and lipid glycosylation is prominently altered in cancer [7]. Carbohydrate antigen CA19-9, the only clinically relevant PDAC biomarker used for therapy follow-up, is a tetrasaccharide cleaved from membrane glycoproteins of epithelial cancer cells and released into the blood. Very recently, a prominent study with targeted CA19-9 overexpression in pancreas of genetically engineered mice suggested not only a biomarker but also a functional role of tissue CA19-9 in progression of
pancreatitis to PDAC and highlighted CA19-9 as a therapeutic target [28].

To date, most of glycan research performed in PDAC focuses on serum biomarkers and specificities in PDAC tissue glycosylation patterns have been rarely addressed. Latest work showed that C1GALT1 controlled glycosylation of cell surface integrins in PDAC cells leads to increased invasiveness and poor patient survival [29] and a very recent MALDI-IMS study performed on formalin-fixed human PDAC FFPE specimens reports on distinct N-glycan populations presented in healthy pancreas and PDAC tissue [17] with high sialylation, poly-LacNAc extensions and fucosylation of high mass N-glycans specifically detected in PDAC. Due to high abundance and functional significance of stroma in PDAC, we postulated that different glycoproteins, GAGs and proteoglycans may be present in the two compartments, cancer cells and stroma, and their biological degradation may generate different glycan fragments. Identification of those fragments may help in addressing the biological differences and functionality of the two compartments.

We used a MALDI-MSI approach on a collection of 109 PDAC patient FFPE samples where the respective stromal and cancer cell compartment was annotated and separately analyzed. Differently than in mentioned recent studies where tissue digestion was used for release on N-glycan bound sugars [17], we used an MALDI-FT-ICR MSI with high mass resolution and accuracy that does not demand tissue pre-treatment. This method was previously optimized by our group [18, 30] and allows detection of naturally occurring unbound, native glycans in FFPE fixed tissues. We identified 8 and 18 glycan fragments uniquely expressed in only stromal or only cancer cell compartment in PDAC, respectively. In both compartments, specific glycans predicting worse or better patient survival were identified, suggesting functional implications of the identified glycans in cancer. It is, however, still difficult to interpret the origin of the identified glycan fragments as they can be biodegradation products of multiple complex proteoglycans and glycosaminoglycans (GAG). Hylauronan and chondroitin sulfate are GAGs that show 12- and 22-fold increase, respectively, in PDAC in comparison with normal pancreas [31]. Hydrolytic cleavage of hylauronan yieldsHexA-HexNAc and HexNAc-HexA-HexNAc fragments [18]. High intensity of those fragments in stroma and tumor, respectively, predicted worse survival in our study, going along with the current view that hyaluronan maintains high interstitial pressure in PDAC stroma, thus hampers the delivery of drugs and imposes lower therapy response and worse prognosis [32]. Enzymatic digestion of

**Table 3** Univariate cox proportional hazard modeling (K–M significant)

| Glycan fragments           | p value (log p) | HR (95% CI) |
|----------------------------|-----------------|-------------|
| **Cancer cell region**     |                 |             |
| HexS                       | 0.023*          | 0.47 (0.24–0.91) |
| dHexHexS                   | 0.028*          | 0.24 (0.058–0.96) |
| HexHexNacAc                | 0.038*          | 0.47 (0.22–0.97) |
| HexHexNacS                 | 0.01*           | 0.39 (0.19–0.82) |
| dHexPenHexAc               | 0.027*          | 0.60 (0.38–0.95) |
| KdoHexAhHexA               | 0.011*          | 0.29 (0.11–0.80) |
| HexHexHexNacS              | 0.023*          | 0.39 (0.17–0.91) |
| HexNacAHexPenHexAc         | 0.012*          | 0.25 (0.079–0.80) |
| dHexHexHexSHexNAc          | 0.011*          | 0.25 (0.079–0.80) |
| HexA                       | 0.012*          | 2.32 (1.19–4.53) |
| Chondroitin or hyaluronan  | 0.007**         | 2.25 (1.23–4.10) |
| HexAHexNAc                 | 0.007**         | 2.25 (1.23–4.10) |
| Chondroitin sulfate        | 0.026*          | 1.74 (1.06–2.85) |
| dHexHexHexAHexMe           | 0.025*          | 2.19 (1.08–4.44) |
| HexAHexNacAHexNAc          | 0.038*          | 2.25 (1.03–4.92) |
| **Stroma region**          |                 |             |
| HexS                       | 0.0028**        | 0.50 (0.32–0.80) |
| N-Acetylgalactosamine sulfate | 0.040*       | 2.00 (1.02–3.91) |
| HexAHexNAc                 | 0.027*          | 1.97 (1.07–3.61) |
| N-Acetylgalactosamine disulfate | 0.020*     | 2.49 (1.12–5.52) |
| HexNAcS                    | 0.012*          | 2.19 (1.17–4.09) |

**p<0.05; **p<0.01

(See figure on next page.)
Fig. 2 (See legend on previous page.)
Fig. 3  

**a** Multivariate factor analysis in cancer cell region

| Glycan Fragment | Factor Loading |
|-----------------|---------------|
| KdoHexAHexA     | 0.9           |
| HexHexNAcS      | 0.9           |
| HexNAcHexPNeuAc | 0.8           |
| HexHexNAcHexNAcS| 0.7           |
| dHexHexHexSHexNAc | 0.7 |
| HexHexHexNAcS   | 0.6           |
| HexHexNAcAc     | 0.6           |
| dHexHexS        |               |
| HexS            |               |
| HexAHexNAc      |               |
| Chondroitin/     |               |
| Hyaluronan      |               |
| HexA            |               |
| HexNAcHexAHexNAc| 0.9           |
| Chondroitin sulfate | 0.6 |
| dHexPentHexAc   |               |
| dHexHexHexAMe   |               |

**b** Multivariate factor analysis in stroma region

**Kaplan-Meier analysis for F1 (factor 1)**

- \( P = 0.0052 \)
- \( \text{HR} = 0.20 (0.05-0.81) \)

**Kaplan-Meier analysis for F2 (factor 2)**

- \( P = 0.0021 \)
- \( \text{HR} = 2.06 (1.18-3.62) \)

**UICC**

- \( P = 0.007 \)
- \( \text{HR} = 1.55 (1.13-2.13) \)

Fig. 3  

**a** Multivariate factor analysis of significant glycan fragments identifies prognostic glycan factors in cancer cell region. 

**b** Multivariate factor analysis of significant glycan fragments identifies prognostic glycan factors in stromal region. The numbers on the arrows pointing from the factors to the individual glycan fragments represent the factor loading of each individual glycan fragment on that factor, which quantifies the extent to which the glycan fragment is related to a given factor. Values close to 1 or \(-1\) represent strong relation, while values close to 0 indicate weak relation. Blue line indicates high score of the factor. Red line indicates low score of the factor.
stromal hyaluronan with hyaluronidases improved delivery of chemotherapeutic drug Gemcitabine into the murine PDAC and prolonged survival [32, 33]. It should also be noted that hyaluronan and chondroitin masses cannot be distinguished at the full mass mode used here. Thus, the mass identified as hyaluronan may as well be chondroitin and must be carefully interpreted.

Chondroitin sulfate (CS) is not only very abundant GAG in the PDAC but also shows alterations in the sulfation pattern of disaccharide chains with dramatically less abundant 4-sulfated disaccharides and more abundant non-sulfated disaccharides than in normal pancreas [31]. Hydrolytic cleavage of CS yields HexS, HexNAcS, HexA–HexNAc, HexA-HexNAcS and HexNAc-HexA-HexNAc fragment signals [18], and these fragments have different predictive values in PDAC tumor and stromal regions. High abundance of HexS in stroma predicts better survival, while HexNAcS and HexAHexNAcS abundance predicts worse survival. In the cancer cell compartment, chondroitin abundance predicts poor survival. At this point, it is difficult to explain those differences, but they might indicate differential activities of sulfatases and sulfotransferases that are responsible for addition and removal of sulfate groups from saccharides creating different abundantly sulfated and non-sulfated glycan fragments in cancer cell and stromal compartment.

It is also important mentioning that we detected Kdo glycan fragments in the cancer cell compartment. Kdo glycan fragments are parts of lipopolysaccharide (LPS) in the outer cell membrane of gram negative bacteria. Recent publications support the existence of intratumoral microbiome in PDAC and even suggest active influence of this microbiome on tumor growth and immune infiltration finally resulting in patient survival differences [34]. The Kdo fragments identified here may originate from the gut microbiota since the gut is in the direct vicinity of the pancreas and there may be surgical cross-contamination between gut and PDAC during biopsy but may also originate from the tumor-specific microbiota. It is tempting to speculate that MALDI-based identification of Kdo fragments may be used for defining the specific intratumoral microbiota. This, however, remains to be addressed in the future studies.

Our multivariate analysis incorporating UICC classification demonstrated that distinct glycan patterns are independent prognostic factors for PDAC patients. Thus, the identified factors and glycan groups may potentially serve clinical prediction purposes. Glycosylated proteins located on the extracellular side of the plasma membrane coordinate the interplay between the cancer cells and the ECM in the tumor microenvironment [14]. Considering the limited number of stroma/cancer cells differentiating glycans determined in our study, these glycans might serve as starting point for further functional analysis.

Conclusions
With our approach, we provide insights into general glyccome differences among the stromal and cancer cell compartment in human PDAC. Our approach using FFPE samples for MALDI-MSI offers a basis for further exploration on role of specific glycans in cancer cell–stroma communication.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13550‑021‑00862‑y.

Additional file 1. Supplementary Figure 1: Correlation of glycan mass intensities and tumor grading (G). All 3 glycans are most abundant in G1 PDACs. Columns indicate mean±standard error. P values calculated with the Kruskal–Wallis test. *P<0.05; **P<0.01; ***P<0.001.

Additional file 2. Supplementary Table 1: Cut-off points and patients survival table of Kaplan–Meier analysis.

Additional file 3. Supplementary Table 2: Multivariate analysis of the prognosis significant glycan fragments with Union for International Cancer Control (UICC) stage. HR-hazard ratio; CI-confidence interval.

Acknowledgements
Not applicable.

Authors’ contributions
NS contributed to data collection and analysis, study design, manuscript drafting and critical revision; FL was involved in data analysis and manuscript drafting; MTA contributed to data analysis, manuscript drafting and critical revision; WY, TK and AF were involved in data collection and analysis; CM contributed to critical revision of the manuscript; KS and AMS were involved in sample collection and organization; WW and IE contributed resources and critical revision of the manuscript; JS was involved in study concept and oversight, resources and critical revision of the manuscript; and AW contributed to study conception and oversight, resources and critical revision of the manuscript. All authors read and approved the final manuscript.
Funding
Open Access funding enabled and organized by Projekt DEAL. This work was supported by German Research Foundation (DFG) within the SFB-Initiative 824 (collaborative research center), “Imaging for Selection, Monitoring and Individualization of Cancer Therapies” (SP8034) and SFB/Transregio 205 S01. J.T.S. is supported by the German Cancer Consortium (DKTK); the Deutsche Forschungsgemeinschaft (DFG) through SFB884 (C4), SI1549/3-1 (Clinical Research Unit KFO337/PhenoTime) and SI1549/4-1; the Deutsche Krebshilfe (German Cancer Aid) through #70112505/PIPAC and #70113834/PREDICT-PACA; and the Wilhelm-Sander-Stiftung through 2019.083.1.

Availability of data and materials
All data presented in this study are available from the corresponding authors upon a reasonable request.

Declarations
Ethics approval and consent to participate
The study was approved by the ethics committee of the Technical University of Munich, Germany (documents no. 1926/2007 and 126/2016S).

Consent for publication
All authors agreed to submission and publication of this article.

Competing interests
WW has attended Advisory Boards and served as speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehinger, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Illumina, Siemens, Agilent, ADC, GSK and Molecular Health. WW receives research funding from Roche, MSD, BMS and AstraZeneca, all outside the submitted work; JTS reports the following disclosures: Bristol-Myers Squibb, Celgene, Roche (Research Funding); AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Immunocore, Novartis, Roche, Shire (Consulting or advisory role); AstraZeneca, Aurikaromed, Basalata, Bristol-Myers Squibb, Celgene, Falk Foundation, iomedico, Immunocore, Novartis, Roche, Shire (Honoria); minor equity in iTheranostics and Pharma15 (< 3%) and member of the Board of Directors for Pharma15, all outside the submitted work. KS reports the following disclosures: MS served as speaker and scientific advisor for Roche, Roche, all outside the submitted work. KS has a patent filed for a radiopharmaceutical compound. KE serves as speaker for Pharma15, all outside the submitted work; JTS reports the following disclosures: JTS is supported by the German Cancer Consortium (DKTK); the Deutsche Forschungsgemeinschaft (DFG) through SFB884 (C4), SI1549/3-1 (Clinical Research Unit KFO337/PhenoTime) and SI1549/4-1; the Deutsche Krebshilfe (German Cancer Aid) through #70112505/PIPAC and #70113834/PREDICT-PACA; and the Wilhelm-Sander-Stiftung through 2019.083.1.

Author details
1 Research Unit Analytical Pathology, Helmholtz Zentrum Munich, 85764 Neuherberg, Germany. 2 Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, 45147 Essen, Germany. 3 Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner Site Essen and German Cancer Research Center, DKFZ, Heidelberg, Germany. 4 Institute of Pathology, TUM School of Medicine, Technical University of Munich, Munich, Germany. 5 Member of the German Cancer Consortium (DKTK), Partner Site, Munich, Germany. 6 Comprehensive Cancer Center Munich (CCCM), Munich, Germany. 7 Institute for Pathology, University Hospital Düsseldorf, Heinrich-Heine University, Düsseldorf, Germany.

Received: 3 August 2021 Accepted: 9 November 2021 Published: 1 December 2021

References
1. Chan-Seng-Yue M, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52(2):231–40.
2. Collisson EA, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–3.
3. Bailey P, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.
4. Aung KL, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial. Clin Cancer Res. 2018;24(6):1344–54.
5. Hosein AN, Brekken RA, Maatta A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487–505.
6. Pinho SS, Reis CA. Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer. 2015;15(8):540–55.
7. Munkley J. The glycosylation landscape of pancreatic cancer. Oncol Lett. 2019;17(3):2569–75.
8. Rosen SD, Bertozzi CR. The selectins and their ligands. Curr Opin Cell Biol. 1994;6(5):663–73.
9. Takahashi S, et al. Overexpression of sialyl Lewis x antigen is associated with formation of extratumoral venous invasion and predicts postoperative development of massive hepatic metastasis in cases with pancreatic ductal adenocarcinoma. Pathobiology. 2001;69(3):127–35.
10. Chugh S, et al. Loss of N-acetylglactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation. Br J Cancer. 2016;114(12):1376–86.
11. Pan S, et al. Large-scale quantitative glycoproteomics analysis of site-specific glycosylation occupancy. Mol Biosyst. 2012;8(11):2850–6.
12. Yue T, et al. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics. 2009;8(7):1697–707.
13. Guillaumond F, et al. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexoseamine biosynthesis in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A. 2013;110(10):3919–24.
14. Peixoto A, et al. Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks. Front Oncol. 2019;9:380.
15. Cai L, et al. Advances in glycosylation-mediated cancer-targeted drug delivery. Drug Discov Today. 2018;23(5):1126–38.
16. Moffitt RA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015;47(10):1168–78.
17. McDowell CT, et al. Imaging mass spectrometry and lectin analysis of N-linked glycans in carbohydrate antigen-defined pancreatic cancer tissues. Mol Cell Proteomics. 2020;20:100012.
18. Kunzke T, et al. Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome. Oncotarget. 2017;8(40):68012–25.
19. Mantini D, et al. LIMPIc: a computational method for the separation of protein MALDI-TOF-MS signals from noise. BMC Bioinformatics. 2007;8:101.
20. Ceroni A, et al. GlycoWorkbench: a tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res. 2008;7(4):1650–9.
21. Kunzke T, et al. Patterns of carbon-bound exogenous compounds in lung cancer patients and association with disease pathophysiology. Cancer Res. 2021. https://doi.org/10.1158/0008-5472.CAN-21-1175
22. Pett MA, Lackey NR, Sullivan JJ. Making sense of factor analysis: the use of factor analysis for instrument development in health care research. London: SAGE Publications, Inc; 2003.
23. Comrey AL, Lee HB. A first course in factor analysis. Hillsdale: Lawrence Erlbaum Associates, Inc.; 1992.
24. Wold S, et al. Multivariate data analysis in chemistry. Berlin: Springer; 1984.
25. McNeil DB, Andersen PK, Batinic-Haberich A, Bendixen H, Bossuyt P, et al. Exploratory and confirmatory factor analysis. Washington, DC: American Psychological Association; 2004.
26. Thompson B. Exploratory and confirmatory factor analysis. London: SAGE Publications, Inc.; 2003.
27. Bielfeld H, et al. Diversity and biology of cancer-associated fibroblasts. Physiol Rev. 2021;101(1):147–76.
28. Angulo DP, et al. The glycans CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science. 2019;364(6446):1156–62.
29. Kuo TC, et al. C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin alphav. Oncogene. 2021;40(7):1242–54.
30. Lu A, et al. High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue. Nat Protoc. 2016;11(8):1428–43.
31. Theocharis AD, et al. Pancreatic carcinoma is characterized by elevated content of hyaluronan and chondroitin sulfate with altered disaccharide composition. Biochim Biophys Acta. 2000;1502(2):201–6.
32. Jacobetz MA, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112–20.
33. Provenzano PP, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–29
34. Riquelme E, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019;178(4):795–806.e12.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.